These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 33278830)

  • 1. Regulatory Safety Learning Driven by the Mechanism of Action: The Case of TNF-α Inhibitors.
    Minnema LA; Giezen TJ; Hoekman J; Egberts TCG; Leufkens HGM; Gardarsdottir H
    Clin Pharmacol Ther; 2021 Jul; 110(1):123-131. PubMed ID: 33278830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment Reports.
    Arnardottir AH; Haaijer-Ruskamp FM; Straus SM; de Graeff PA; Mol PG
    Drug Saf; 2011 Nov; 34(11):1101-14. PubMed ID: 21981437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Information on adverse drug reactions-Proof of principle for a structured database that allows customization of drug information.
    Kusch MKP; Zien A; Hachenberg C; Haefeli WE; Seidling HM
    Int J Med Inform; 2020 Jan; 133():103970. PubMed ID: 31704490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADR databases for on-site clinical use: Potentials of summary of products characteristics.
    Eiermann B; Rodriguez D; Cohen P; Gustafsson LL
    Basic Clin Pharmacol Toxicol; 2021 Apr; 128(4):557-567. PubMed ID: 33523597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Adverse Drug Reaction Database for Clinical Use - Potential of and Difficulties with the Summary of Product Characteristics.
    Eiermann B; Rodrigues D; Cohen P; Gustafsson LL
    Stud Health Technol Inform; 2022 May; 294():450-454. PubMed ID: 35612120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients.
    Giraud EL; Jessurun NT; van Hunsel FPAM; van Puijenbroek EP; van Tubergen A; Ten Klooster PM; Vonkeman HE
    Expert Opin Drug Saf; 2020 Dec; 19(12):1617-1624. PubMed ID: 32990050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in adverse drug reactions listed in product information for antidepressants and anticonvulsants, between the USA and Europe: a comparison review of paired regulatory documents.
    Cornelius VR; Liu K; Peacock J; Sauzet O
    BMJ Open; 2016 Mar; 6(3):e010599. PubMed ID: 26996819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of serious adverse drug reactions using FDA-approved drug labeling and MedDRA.
    Wu L; Ingle T; Liu Z; Zhao-Wong A; Harris S; Thakkar S; Zhou G; Yang J; Xu J; Mehta D; Ge W; Tong W; Fang H
    BMC Bioinformatics; 2019 Mar; 20(Suppl 2):97. PubMed ID: 30871458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
    Jose J; Rao PG
    Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Three Different Data Sources of Adverse Drug Reactions Using Adverse Drug Reaction Data of Fluorouracil for Gastric Cancer as an Example.
    Niu R; Chen Y; Xiang Y; Liu Y; Guo J; Feng B
    Biol Pharm Bull; 2020; 43(10):1476-1480. PubMed ID: 32999157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and quality of adverse drug reaction reports by pharmacists in Norway.
    Gedde-Dahl A; Harg P; Stenberg-Nilsen H; Buajordet M; Granas AG; Horn AM
    Pharmacoepidemiol Drug Saf; 2007 Sep; 16(9):999-1005. PubMed ID: 17457794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks Associated with the Use of Intranasal Corticosteroids: An Analysis of Adverse Reactions Reported to EudraVigilance.
    Martins L; Silvestre S; Monteiro C
    Healthcare (Basel); 2024 Sep; 12(19):. PubMed ID: 39408103
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are non-serious adverse reactions to psychiatric drugs really non-serious?
    Pozzi M; Bertella S; Cattaneo D; Molteni M; Perrone V; Carnovale C; Antoniazzi S; Clementi E; Radice S
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):394-400. PubMed ID: 23952186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reaction labelling for atomoxetine, methylphenidate and modafinil: comparison of product information for oral formulations in Australia, Denmark and the United States.
    Aagaard L; Hansen EH
    Curr Drug Saf; 2013 Jul; 8(3):162-8. PubMed ID: 23914751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment.
    Weersink RA; Timmermans L; Monster-Simons MH; Mol PGM; Metselaar HJ; Borgsteede SD; Taxis K
    Front Pharmacol; 2019; 10():1031. PubMed ID: 31607904
    [No Abstract]   [Full Text] [Related]  

  • 19. Factors associated with spontaneous reporting of adverse drug reactions in Japan.
    Yamada T; Watanabe Y; Kusama M; Sugiyama Y; Ono S
    Pharmacoepidemiol Drug Saf; 2013 May; 22(5):468-76. PubMed ID: 23172714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety learning from drugs of the same class: room for improvement.
    Stefansdottir G; Knol MJ; Arnardottir AH; van der Elst ME; Grobbee DE; Leufkens HG; De Bruin ML
    Clin Pharmacol Ther; 2012 May; 91(5):872-80. PubMed ID: 22453192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.